Onset of VLST | P Value | |||
---|---|---|---|---|
All (n=98) | Earlier (n=49) | Delayed (n=49) | ||
Full stent length | ||||
Analyzed frames | 26.0 (20.0–32.3) | 26.0 (20.5–33.0) | 26.0 (20.0–32.0) | 0.939 |
Analyzed struts | 172.5 (126.5–241.3) | 183.0 (142.0–246.0) | 163.0 (110.5–221.5) | 0.309 |
Stent CSA, mm2 | 7.5 (6.0–8.4) | 6.9 (5.5–8.2) | 7.8 (6.2–8.5) | 0.073 |
Lumen CSA, mm2 | 4.1 (3.0–5.3) | 4.4 (3.3–5.8) | 4.0 (2.7–4.9) | 0.124 |
Malapposed struts (%) | 1.2 (0–5.0) | 1.3 (0–5.2) | 1.2 (0–4.9) | 0.692 |
Uncovered struts (%) | 5.0 (0.9–5.2) | 5.0 (2.8–9.9) | 2.6 (0–5.1) | 0.033 |
Thrombosed regions | ||||
Analyzed frames | 4.0 (3.0–6.0) | 3.0 (2.3–5.8) | 4.0 (3.0–6.0) | 0.484 |
Analyzed struts | 17.0 (11.0–32.3) | 18.0 (11.0–34.8) | 17.0 (11.0–32.0) | 0.588 |
Stent CSA, mm2 | 7.6 (6.1–8.6) | 7.2 (6.0–8.4) | 7.8 (6.1–8.8) | 0.222 |
Lumen CSA, mm2 | 2.5 (1.4–5.4) | 2.1 (1.4–5.4) | 2.5 (1.5–5.4) | 0.736 |
Minimum stent CSA, mm2 | 7.1 (5.5–8.1) | 6.5 (5.1–7.7) | 7.4 (5.7–8.2) | 0.147 |
Stent underexpansion | 18 (18.4) | 11 (22.4) | 7 (14.3) | 0.297 |
Minimum lumen CSA, mm2 | 1.5 (0.9–3.8) | 1.4 (0.9–4.4) | 1.7 (0.8–3.6) | 0.949 |
Malapposed struts (%) | 25.0 (15.0–37.3) | 28.0 (14.5–37.3) | 20.1 (14.9–38.4) | 0.957 |
Maximal distance of malapposed struts, μma | 710.0 (465.0–1175.0) | 890.0 (555.0–1200.0) | 520.0 (410.0–1055.0) | 0.191 |
Uncovered struts (%) | 14.6 (0–35.0) | 33.3 (0–35.1) | 0 (0–35.4) | 0.057 |
Primary cause of VLST | ||||
Stent malapposition | 33 (33.7) | 17 (34.7) | 16 (32.7) | 0.831 |
Evagination | 3 (3.1) | 0 (0) | 3 (6.1) | 0.242 |
Uncovered struts without stent malapposition or evagination | 24 (24.5) | 17 (34.7) | 7 (14.3) | 0.019 |
Neoatherosclerosis | 34 (34.7) | 12 (24.5) | 22 (44.9) | 0.034 |
Neointimal erosion without neoatherosclerosis | 4 (4.1) | 3 (6.1) | 1 (2.0) | 0.617 |
Data are presented as number (percentage) or median (interquartile range). CSA indicates cross‐sectional area; VLST, very late stent thrombosis.
↵a Compared within patients having malapposed struts.